Self-assembly of polyesters like PLLA and PDLA into stereocomplexes (SCs) is an interesting approach to tailor physical properties of polymeric nanoparticles without affecting their hydrophilicity. Here, we use the stereocomplexation of P(LLA-stat-EtGly) and P(DLA-stat-EtGly) (EtGly: 3-ethylglycolide) to tune the melting temperature (T m ) and degree of crystallinity (w c ) of the bulk polymer. Using time-dependent blending experiments and characterization techniques, such as dynamic light scattering, wide-angle X-ray spectroscopy, differential scanning calorimetry, and atomic force microscopy, we tested the hypothesis that the amount of SCs within the nanoparticles impacts their mechanical properties. Our results show that T m and w c can be adjusted via the EtGly content. Interestingly, mechanical properties of the nanoparticles depend on the EtGly content as well as the self-assembly time of SCs before nanoparticle formation. This offers a high potential for their application in drug delivery, where their tunable properties will allow to adjust degradation and drug release behavior.

Within this open observational study, repeated PCR ( n  > 4,700) and antibody screening ( n  > 1,600) tests were offered in three different working fields. The study identified 51 subjects with acute SARS-CoV-2 infection and 37 subjects reported to have had a positive PCR test taken externally.

For improved cost-effectiveness and temperaturestability, a ready to use lateral flow assay (LFA) is developed in this work for detecting inflammation/infection biomarker C-reactive protein (CRP) in human patient samples on the basis of aptamers. In prescreening investigations, an aptamer with CRP affinity was immobilized on microarray chips in forward and sandwich formats to optimize assay conditions. We suggest these microarray techniques as a resource-sparing and fast-screening instrument for evaluation of various conditions. The capability of the aptamer to detect CRP was shown. Optimized assay conditions were consequently transferred to the LFA-platform. Here we could demonstrate for the first time an aptamer-based LFA for the detection of CRP in human patient samples in pathologically relevant concentrations. The cutoff for CRP detection is set at 10 mg/L, providing a distinctive "yes" (≥10 mg/L CRP) or "no" (<10 mg/L CRP) answer for the patient. The resulting aptamer-based LFA is promising with regard to its application as point-of-care testing (POCT) for efficient monitoring, especially of patients affected by frequent infections or inflammations.

No abstract